【外媒】MannKind携手赛诺菲欲创销售奇迹

仲夏秋夜云

小编语：If you can't beat 'em, join 'em。这句挺霸气的话。如果打不赢他们，就加入他们。
Mannkind这点做得很好。与其和赛诺菲、礼来等具体争糖尿病药物市场，不如携手开拓，利益抽成……雪球就是这样滚大的。
何况吸入式的胰岛素看起来很新，但曾经有过治疗哮喘的药物好像也是吸入式的，最后因为使用不方便，没有占领到任何市场。
好吧，其实中国也有句话话：大树底下好乘凉。该傍大腿的时候还是要傍的。

以下是外媒报道：

MannKind recruits Sanofi to hawk Afrezza in $925M marketing deal

August 11, 2014 | By Carly Helfand
MannKind ($MNKD) has adopted an "If you can't beat 'em, join 'em" strategy for its newly approved Afrezza. Instead of going up against diabetes giants the likes of Sanofi ($SNY), MannKind is joining hands with the French drugmaker in a marketing partnership worth up to $925 million.
Sanofi will fork over $150 million upfront for Afrezza and up to $775 million more if the med hits certain sales and development targets, the companies said Monday. The pair will share global profits and losses, with Sanofi taking 65%. The Paris-based pharma has also agreed to advance to MannKind its share of the collaboration's expenses, with a ceiling of $175 million.
For Sanofi, which already boasts the world's best-selling diabetes med in Lantus, Afrezza is an addition to a well-stocked insulin therapy lineup. But while the company may be well-versed in the way of diabetes marketing, that doesn't mean selling Afrezza will be easy. The new drug will take on mealtime insulins NovoLog from Novo Nordisk ($NVO) and Humalog from Eli Lilly ($LLY), both blockbusters in their own right.
And then there's the looming specter of Pfizer's ($PFE) inhaled insulin Exubera, a one-time-blockbuster-hopeful-turned-colossal-flop that Pfizer yanked from the market back in 2007. Sanofi reps will have to convince doctors that Afrezza, unlike its predecessor, can get the job done.
The newcomer therapy does have at least one leg up on Pfizer's failure in its Dreamboat inhaler--a coach's whistle-shaped device that makes Exubera's larger, bulkier predecessor look like the Titanic. Back in the day, Exubera patients were also put off by the need for periodic lung function tests, Reuters notes.
Regardless of how rocky the road ahead may be, MannKind CEO Alfred Mann said he was  "so very pleased and honored" to have Sanofi on board, calling it a perfect match to help his company on its quest for the $1 billion in sales that analysts predict by 2019.
"Sanofi is the ideal partner given their complementary product portfolio, their vast insulin market presence and a leading global commercial infrastructure," he said in a statement.

yuansoul

不要欺负小孩，因为他们会长大。

yuansoul

反对楼主英文引用观点。打不赢就加入。。。。韩信、卧薪尝胆。。。。越战。。。

仲夏秋夜云

yuansoul 发表于 2014-8-12 09:56
反对楼主英文引用观点。打不赢就加入。。。。韩信、卧薪尝胆。。。。越战。。。

这是引用文章里的

yuansoul

仲夏秋夜云 发表于 2014-8-12 10:37
这是引用文章里的

恩，最讨厌不学历史的。

syhorchid

如果打不赢他们，就加入他们。